Biohaven Ltd. has reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder (MDD). The study did not meet its primary endpoint, showing no significant reduction in depressive symptoms compared with placebo as measured by the Montgomery Åsberg Depression Rating Scale (MADRS) over six weeks. Trends favoring BHV-7000 were observed in certain subgroups, such as participants with more severe depression at baseline. BHV-7000 was generally safe and well-tolerated, with adverse events primarily mild or moderate and mostly resolving on their own. The company does not plan additional psychiatric clinical trials for BHV-7000 and will focus on other priority areas. Additional analyses are ongoing, and Biohaven plans to present the results at an upcoming scientific meeting. The company also intends to provide further updates on its clinical programs, including data from its extracellular degrader programs and other assets, at the J.P. Morgan Healthcare Conference in January 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE53533) on December 24, 2025, and is solely responsible for the information contained therein.